{
  "id": 13894408,
  "title": "Enliven Therapeutics director Scott Garland sells $606k in stock",
  "url": "https://urgent.news/2026/10/12/enliven-therapeutics-director-scott-garland-sells-606k-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T06:45:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/enliven-therapeutics-director-scott-garland-sells-606k-in-stock-93CH-4943248"
  },
  "original_language": "en",
  "account": null,
  "summary": "Enliven Therapeutics director Scott Garland sold $606,719 worth of the company's common stock on October 1, 2026, following an option exercise. Garland disposed of 13,000 shares at an average price of $46.6707 per share, trading at $40.98, down nearly 10% over the past week. Despite the recent decline, the stock has delivered a strong 97% return over the past year. The shares Garland sold were acquired through the exercise of stock options, with the original option grant for 59,372 shares vesting over time contingent on his continued service as an outside director. Recent developments include an agreement with the FDA on the design of Enliven's Phase 3 study, ENABLE-2, which will evaluate relcobatinib (ELVN-001) in chronic myeloid leukemia patients. Analysts have shown increasing interest in Enliven Therapeutics, with Morgan Stanley, JPMorgan, and Barclays initiating coverage with Overweight ratings and price targets ranging from $70.00 to $78.00.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Monopar Therapeutics director Christopher Starr sells shares worth $659k",
        "url": "https://urgent.news/2026/10/12/monopar-therapeutics-director-christopher-starr-sells-shares-worth",
        "published": "2026-10-12T00:01:06.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}